Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: Investigational (Tier 3)GRADE: Low

Investigational / Research Priority

ENT applications of hirudotherapy are not included in FDA 510(k) clearance for Hirudo verbana. The evidence below reflects international clinical experience. All ENT indications represent off-label use.

Investigational Application

Otolaryngology is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

The middle ear, paranasal sinuses, and cochlea share end-arterial blood supply, narrow drainage, and fractional-millimeter tolerance for edema. ENT hirudotherapy is documented across 259+ patients in seven investigations (1935-2003): chronic SNHL (n=104), sinusitis (n=60), vasomotor rhinitis (n=55), cochleovestibular disorders (n=40), and inflammatory ear disease. No randomized controlled trial exists for any ENT indication.

Fundamento biológico

Microcirculation & Anti-Inflammatory

Histamine-like vasodilator increases periauricular/paranasal capillary flow. Hyaluronidase facilitates lymphatic drainage. Eglins block elastase/cathepsin G; LDTI attenuates mast cell mucosal inflammation; C1s complement inhibitor modulates classical pathway — relevant to sinusitis and neuritis.

Anticoagulant & Lipid

Hirudin prevents fibrinogen clotting. Calin/saratin inhibit platelet adhesion. Destabilase-M lyses fibrin. Lipase and cholesterol esterase reduce circulating lipids. Together these target cochlear ischemia from vertebrobasilar atherosclerosis.

Rationale is strongest for vascular ENT disorders (cochlear ischemia, posterior circulation ischemia, hypercoagulable states), where multiple SGS components directly target pathophysiology.

Evidencia clínica

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

Otolaryngology — International Clinical Evidence
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Seleznev & Shchetinina 1990	Protocol guidelines + case series	Neuritis, tinnitus, otitis, trigeminal neuralgia (n=NR)	1-5 leeches; 2-9 sessions; mastoid, tragus, application sites	Pain, audiometric noise, electroconductivity	Pain resolved 1-2 sessions; decreased tinnitus; shortened disability In Baskova et al. guidelines; n not reported; Level IV
Grigoryev et al. 1998	Case series	Chronic otitis media with vascular comorbidity (n=NR)	Leeches to vertebrobasilar region	Blood biochemistry, neurological symptoms	Hypercoagulable profile corrected; neurological symptoms resolved Vascular comorbidity mimicking otogenic complications; Level IV
Grigoryev & Krymskaya 1998	Case series	Cochleovestibular disorders, peripheral origin (n=40)	Mastoid application sites; 15-20 min exposure	Tinnitus, head heaviness	All 40: reduced tinnitus; subjective lightness in head Vascular etiology; bleeding up to 5h; Level IV
Zhuravsky 2000	Prospective cohort (doctoral thesis)	Chronic SNHL: vascular, neurogenic, presbycusic, ototoxic (n=104)	1-4 leeches; 25-30 weekly sessions; 8-site rotation	Audiometry, speech comprehension, histology (animal)	Audiometric gain (vascular); speech comprehension (presbycusis); stabilization (ototoxic) Largest ENT study; preclinical histologic data; Level IV
Moskalenko 2001	Case series	Acute sinusitis (n=60)	Endonasal bilateral; 1-5 sessions; 2-10 leeches total	Headache, sinus puncture avoidance, antibiotics	Headache reduced; sinus puncture avoided; antibiotics eliminated Clinically significant procedural sparing; Level IV
Krymskaya et al. 2003	Prospective cohort	Vasomotor rhinitis: idiopathic (20), drug-induced (35) (n=55)	Endonasal via syringe device; 2-6 sessions q2-3d	Nasal breathing, medication need; 3-4 month follow-up	Immediate breathing restoration; 3/55 required medication at follow-up AE: septal hematoma 1.8%, allergic rhinorrhea 9.1%; Level IV
Zhuravsky 2000	Animal histologic study (preclinical)	Membranous labyrinth (animal model) (n=NR)	Hirudotherapy in experimental animals	Hair cell activity, capillary density, neuroepithelium	Enhanced hair cells; increased stria vascularis capillaries; neuroprotection Structural basis for audiometric improvements; preclinical

All ENT evidence is Level IV (case series, uncontrolled cohorts). No RCT has been performed. Sham leech devices used in other specialties could be adapted for periauricular application.

Enfermedad inflamatoria del oído — Protocolo de Seleznev y Shchetinina (1990)

Indication	Leeches	Sessions	Placement	Exposure
Acute auditory nerve neuritis	1-3/side	5-9	Mastoid, 1 cm from auricle; bilateral	Full engorgement
Tinnitus (chronic neuritis)	1-3	5-9	Acupuncture points, affected side	3-5 min
Acute external otitis	1-3	2-4	Mastoid; tragus; inflammation site	5-7 min
Non-perforative otitis media	2-5	2-4	Mastoid; tragus	3-5 min
Adhesive otitis media	2-5	4-7	Mastoid; tragus	3-5 min
Secondary trigeminal neuralgia	1-3	2-4	Trigeminal nerve exit points	3-5 min

Pain resolved after 1-2 sessions in most cases. Audiometric testing showed decreased tinnitus intensity, skin electroconductivity increased, tissue oxygenation rose, and disability duration shortened.

Hipoacusia neurosensorial crónica — Zhuravsky (2000), n=104

The largest ENT hirudotherapy study examined 104 patients with chronic SNHL using an 8-site rotation protocol (25-30 weekly sessions, 1-4 leeches each). Outcomes varied by etiology:

Vascular/Neurogenic

Audiometric threshold improvement. SGS anticoagulant/vasodilatory actions directly target cochlear ischemia from vertebrobasilar compromise. Strongest etiologic response.

Presbycusis

Improved speech comprehension without pure-tone threshold change — central neurovascular processing benefit rather than peripheral hair cell recovery.

Secondary (Middle Ear)

Reduction in both conductive and sensorineural components — combined mechanism via decongestion and microvascular improvement.

Ototoxic/Postinfectious

Nonspecific stabilization of remaining function — neuroprotective rather than regenerative effect.

Preclinical component: animal model histology showed enhanced hair cell activity, increased stria vascularis capillary density, and protective effect on spiral organ neuroepithelium — structural basis for the audiometric findings.

Trastornos cocleovestibulares

Grigoryev & Krymskaya (1998) — n=40

Peripheral cochleovestibular disorders with vascular etiology (hypertension, atherosclerosis). Elevated cholesterol, beta-lipoproteins, fibrinogen; shortened clotting time. Leeches on mastoid application sites, 15-20 min. All 40 patients: reduced tinnitus, subjective head lightness, corrected hypercoagulable profile.

Sinusitis aguda

Moskalenko (2001) — n=60

Endonasal bilateral application; full engorgement; 1-5 sessions; 2-10 leeches total. Near-universal headache reduction. Treatment shortened. Maxillary sinus puncture avoided — eliminating an invasive procedure with orbital/intracranial complication risk. Antibiotic courses eliminated. This represents a substantial reduction in procedural burden: sinus puncture/lavage is the standard Russian ENT intervention for refractory acute sinusitis.

Rinitis vasomotora

Krymskaya et al. (2003) conducted the most detailed endonasal study: 55 patients — 20 idiopathic, 35 drug-induced (rhinitis medicamentosa); 25/35 on antihypertensives. All underwent pre-treatment sinus probing/lavage to exclude purulent disease. Endonasal application to anterosuperior nasal septum via syringe containment device; 2-6 sessions at 2-3 day intervals.

Outcomes

Immediate: Improvement or complete restoration of nasal breathing; disappearance of head heaviness; resolution of ear congestion
3-4 month follow-up: Only 3/55 patients required medication — remarkable reduction in drug dependence
Pain: No patient reported procedural pain (0/55)

Adverse Events

Septal hematoma: 1/55 (1.8%) — premature mucocapillary closure; requires prompt drainage
Allergic rhinorrhea: 5/55 (9.1%) — managed with antihistamines; treatment continued
9.1% allergic rate is higher than 2-5% cutaneous, possibly from nasal mucosal immunoreactivity

Investigators recommended endonasal hirudotherapy as the therapy of choice for idiopathic and drug-induced vasomotor rhinitis — a strong recommendation given the limited alternatives for rhinitis medicamentosa. Based on Level IV evidence without a control group.

Protocolo clínico

Patient Selection & Pre-Procedure

Candidates include patients with otitis, auditory neuritis/tinnitus, chronic SNHL (vascular/neurogenic/presbycusic), acute sinusitis, vasomotor rhinitis, and cochleovestibular disorders with vascular comorbidity. All patients must receive concurrent standard ENT care. Pre-procedure workup: audiometry for hearing indications; sinus probing/lavage to exclude purulent sinusitis (mandatory before endonasal application); blood biochemistry (cholesterol, fibrinogen, prothrombin index); coagulation panel; vertebrobasilar Doppler for vascular etiology; medication review.

Parameter	Otitis / Neuritis	Chronic SNHL	Sinusitis	Rhinitis
Site	Mastoid, 1 cm from auricle	8-site rotation	Nasal septum bilateral	Nasal septum anterosuperior
Leeches	1-5/session	1-4/session	2-10 total	1-2/session
Sessions	2-9; q2-3d	25-30; weekly	1-5; q2d	2-6; q2-3d
Exposure	3-7 min or full	Full engorgement	Full engorgement	Full engorgement

Endonasal Technique

Containment: 2-mL syringe (plunger/tip removed) as hollow cylinder
Site: Anterosuperior nasal septum
Bilateral: Both nares simultaneously
Position: Seated, head tilted back; continuous monitoring
Post-procedure: Monitor for septal hematoma (24-48h) and rhinorrhea

Post-Procedure

Sterile dressing (expect oozing up to 5h periauricular). Audiometric follow-up at course completion. Repeat sinus lavage for obstruction assessment. Blood biochemistry for vascular patients. Nasal septum check at 24-48h post-endonasal. Vasomotor rhinitis: 3-4 month reassessment.

Consideraciones de seguridad

Endonasal bleeding: Kiesselbach plexus = prolonged bleeding. Nasal packing must be available. Contraindicated with anticoagulants without risk-benefit assessment
Septal hematoma: 1/55 (1.8%); requires prompt drainage to prevent abscess, cartilage necrosis, saddle-nose deformity
Leech migration (nasal): Aspiration hazard if leech reaches nasopharynx. Syringe containment + continuous monitoring mandatory
Leech migration (ear canal): Limit to lateral cartilaginous canal; continuous visual monitoring to prevent tympanic membrane contact
Allergic rate: 9.1% endonasal vs 2-5% cutaneous; manage with antihistamines
Infection: Aeromonas hydrophila — nasal cavity proximity to sinuses/cavernous sinus. Prophylactic fluoroquinolone or TMP-SMX for endonasal use
Contraindications: Tympanic membrane perforation; active purulent sinusitis; uncontrolled anticoagulation; known Hirudo allergy; immunocompromise; pediatric patients (not studied)

Drug Interactions

Anticoagulants/antiplatelets: Additive bleeding. Relative contraindication endonasal; coagulation monitoring periauricular; nasal packing available
Nasal decongestants: Discontinue before endonasal (therapeutic for rhinitis medicamentosa)
Antihypertensives: Monitor BP; 25/55 rhinitis patients tolerated concurrent use
Prophylactic antibiotics: Consider fluoroquinolone/TMP-SMX for endonasal applications (Aeromonas prophylaxis)

Estatus regulatorio

No regulatory clearance exists for ENT leech applications in the US, EU, or other major jurisdictions. FDA 510(k) K040885 clearance of Hirudo verbana is limited to venous congestion in surgical flaps/replantation. All ENT applications are off-label. In Russia, hirudotherapy is included in ENT protocols at specialist clinics within the national complementary medicine framework.

Informed consent must address: investigational nature, absence of FDA clearance for ENT use, Level IV evidence base, and unique safety considerations of endonasal and ear canal application.

Brechas de evidencia y prioridades de investigación

No RCT exists for any ENT indication. However, ENT disease offers standardized audiometric/imaging endpoints, quantifiable blood biomarkers, and established comparators (sinus puncture, decongestant withdrawal) that make rigorous investigation feasible. ASH supports development of controlled studies for:

Chronic SNHL (Priority 1): RCT of HT + standard care vs. standard care in vascular/neurogenic SNHL; audiometric primary endpoint; vertebrobasilar Doppler mechanistic endpoint
Acute sinusitis (Priority 2): Non-inferiority trial vs. maxillary sinus puncture; CT clearance endpoint; procedural burden and antibiotic use secondary
Vasomotor rhinitis (Priority 3): Controlled comparison vs. gradual decongestant withdrawal; rhinomanometry and medication-free days endpoints
Mechanistic studies (Priority 4): SGS effects on mucosal inflammation biomarkers (IL-6, TNF-alpha, mast cell tryptase) and cochlear blood flow (gadolinium MRI or OCT angiography)

Conclusiones clave

Largest ENT evidence: 104 SNHL patients (Zhuravsky 2000) with audiometric + preclinical histologic data. Vascular/neurogenic etiology showed strongest response.

Vasomotor rhinitis: 3-4 month sustained breathing restoration; 3/55 required medication. Recommended as therapy of choice (Krymskaya 2003).

Sinusitis: Sinus puncture avoided in 60 patients (Moskalenko 2001) — meaningful procedural sparing.

All Level IV: No RCTs, but ENT offers standardized audiometric/imaging endpoints for rigorous studies. Endonasal risks (migration, hematoma, 9.1% allergy) require specialized training.

Otorrinolaringología